Kiniksa Pharmaceuticals is a drug manufacturers - specialty & generic business based in the US. Kiniksa Pharmaceuticals shares (KNSA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $26.32 – an increase of 3.26% over the previous week. Kiniksa Pharmaceuticals employs 297 staff and has a trailing 12-month revenue of around $338.9 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $26.32 |
|---|---|
| 52-week range | $14.12 - $27.92 |
| 50-day moving average | $25.36 |
| 200-day moving average | $21.08 |
| Wall St. target price | $34.20 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.15 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $27.06 from 2024-10-15
| 1 week (2024-10-11) | 1.88% |
|---|---|
| 1 month (2024-09-18) | 7.08% |
| 3 months (2024-07-18) | 27.88% |
| 6 months (2024-04-18) | 60.31% |
| 1 year (2023-10-18) | 62.52% |
|---|---|
| 2 years (2022-10-18) | 107.04% |
| 3 years (2021-10-18) | 153.13% |
| 5 years (2019-10-18) | 416.41% |
| Revenue TTM | $338.9 million |
|---|---|
| Gross profit TTM | $173.2 million |
| Return on assets TTM | -3.35% |
| Return on equity TTM | -2.42% |
| Profit margin | -3.02% |
| Book value | $6.12 |
| Market Capitalization | $1.9 billion |
TTM: trailing 12 months
We're not expecting Kiniksa Pharmaceuticals to pay a dividend over the next 12 months.
Kiniksa Pharmaceuticals's shares were split on 27 June 2024.
Over the last 12 months, Kiniksa Pharmaceuticals's shares have ranged in value from as little as $14.12 up to $27.92. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kiniksa Pharmaceuticals's is 0.32. This would suggest that Kiniksa Pharmaceuticals's shares are less volatile than average (for this exchange).
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024. The company was incorporated in 2015 and is based in London, the United Kingdom. .
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
What you need to know about investing in the leading indicator for the overall US stock market.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Read our beginner’s guide to trading options in the US.